Market capitalization | $4.26m |
Enterprise Value | $-6.61m |
P/E (TTM) P/E ratio | negative |
EV/Sales (TTM) EV/Sales | -0.83 |
P/S ratio (TTM) P/S ratio | 0.53 |
P/B ratio (TTM) P/B ratio | 0.43 |
Revenue growth (TTM) Revenue growth | 15.31% |
Revenue (TTM) Revenue | $8.01m |
EBIT (operating result TTM) EBIT | $-6.36m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
1 Analyst has issued a forecast Brickell Biotech Inc:
1 Analyst has issued a forecast Brickell Biotech Inc:
Dec '23 |
+/-
%
|
||
Revenue | 8.01 8.01 |
15%
15%
|
|
Gross Profit | 7.92 7.92 |
-
|
|
EBITDA | -6.28 -6.28 |
71%
71%
|
EBIT (Operating Income) EBIT | -6.36 -6.36 |
70%
70%
|
Net Profit | -5.89 -5.89 |
72%
72%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.
Head office | United States |
CEO | Albert Marchio |
Employees | 4 |
Founded | 2009 |
Website | www.frtx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.